abs277.txt	objective		this	study	explored	neoplasm	risk	with	liraglutide	versus	placebo	inthe	leader	(liraglutide	effect	and	action	in	diabetes	evaluation	ofcardiovascular	outcome	results)	cohort	research	design	methods	(nct01179048)	was	an	international	phase	3b	randomized	double-blind	controlled	trial	participants	aged	≥50	years	type2	high	cardiovascular	were	assigned	1	to	receive	liraglutide(≤1	8	mg	daily	n	=	4	668)	or	(n	672)	addition	standard	careand	monitored	for	3	5-5	(median	follow-up	years)	the	occurrence	ofneoplasms	a	prespecified	exploratory	secondary	end	point	post	hoc	analysesof	time	first	confirmed	neoplasms	conducted	using	coxregression	model	results	10	1%	of	patients	9	0%with	(hazard	ratio	[hr]	12	[95%	ci	0	99	28])	hr	(95%	ci)	forliraglutide	06	(0	90	25)	malignant	16(0	93	44)	benign	sensitivity	analyses	excluding	neoplasmsoccurring	<1	year	<2	after	randomization	by	sex	providedsimilar	our	main	95%	included	one	allmalignant	evaluated	(including	pancreatic	thyroid	neoplasms)	exceptfor	prostate	which	occurred	fewer	liraglutide-treated	conclusions	not	primarily	designed	assess	firmconclusions	cannot	be	made	regarding	numeric	imbalances	observed	individualneoplasm	types	(e	g	cancer)	that	infrequently	datado	however	exclude	major	increase	total	neoplasmswith	additional	studies	are	needed	assesslonger-term	exposure
